Want to see STIM full AI Analyst Report?
STIM Stock Chart & Stats
$1.73
$0.08(4.62%)
At close: 4:00 PM EDT
$1.73
$0.08(4.62%)
Day’s Range― - ―
52-Week Range$0.80 - $3.71
Previous Close$1.8
Volume807.96K
Average Volume (3M)1.96M
Market Cap
$228.59M
Enterprise Value$160.20
Total Cash (Recent Filing)$19.43M
Total Debt (Recent Filing)$86.52M
Price to Earnings (P/E)―
Beta1.95
Next Earnings
Nov 10, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding76,197,220
10 Day Avg. Volume3,223,854
30 Day Avg. Volume1,959,322
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)4.07
Price to Sales (P/S)0.61
P/FCF Ratio-4.30
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.00Price Target Upside189.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.46
Revenue Forecast (FY)$161.13M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthRapid top-line expansion, led by Greenbrook, indicates stronger adoption of the company’s neurohealth platform. Sustained clinic growth can increase treatment volume, recurring service demand, and the installed base over the next several quarters.
Improving Margins And Cost DisciplineHigher gross margin and lower operating expenses demonstrate tangible progress toward operating leverage. If mix, pricing, and cost controls persist, these improvements can reduce losses and support a more durable path toward positive cash generation.
Expanded NeuroStar Commercial ModelOffering multiple purchasing and financing structures broadens access to NeuroStar and may reduce upfront barriers for providers. A larger installed base can create recurring consumables and support revenue, although execution remains important during the transition.
Bears Say
Persistent Losses And Negative Cash FlowThe company has not yet converted revenue growth into sustainable cash generation. Continued operating and investing cash use may require additional financing, limiting strategic flexibility and increasing execution risk until operations consistently fund the business.
High Financial LeverageHigh leverage leaves Neuronetics more exposed to refinancing needs and reduces its ability to absorb operational setbacks. The balance sheet therefore places greater importance on achieving sustained profitability and cash generation to stabilize capitalization.
NeuroStar Transition And Clinic UnderutilizationDeclining session utilization and substantial unused clinic capacity constrain recurring treatment revenue and fixed-cost absorption. The shift toward purchase and lease models also creates execution and comparability risks while the company establishes a sustainable commercial mix.
Neuronetics News
STIM FAQ
What was Neuronetics’s price range in the past 12 months?
Neuronetics lowest stock price was $0.80 and its highest was $3.71 in the past 12 months.
What is Neuronetics’s market cap?
Neuronetics’s market cap is $228.59M.
When is Neuronetics’s upcoming earnings report date?
Neuronetics’s upcoming earnings report date is Nov 10, 2026 which is in 77 days.
How were Neuronetics’s earnings last quarter?
Neuronetics released its earnings results on Aug 11, 2026. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.123 by $0.073.
Is Neuronetics overvalued?
According to Wall Street analysts Neuronetics’s price is currently Undervalued.
Does Neuronetics pay dividends?
Neuronetics does not currently pay dividends.
What is Neuronetics’s EPS estimate?
Neuronetics’s EPS estimate is -0.09.
How many shares outstanding does Neuronetics have?
Neuronetics has 76,197,220 shares outstanding.
What happened to Neuronetics’s price movement after its last earnings report?
Neuronetics reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.123. Following the earnings report the stock price went up 47.005%.
Which hedge fund is a major shareholder of Neuronetics?
Currently, no hedge funds are holding shares in STIM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neuronetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (189.02% Upside)
$5.00 (189.02% Upside)
Blogger Sentiment
Bullish
STIM Sentiment 67%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $44.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.4%
Last 30 Days ▲ 6.9%
Last 30 Days ▲ 6.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-61.12%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.32%
Trailing 12-Months
Company Description
Neuronetics
Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.
STIM Company Deck
STIM Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed measurable operational and financial progress: revenue growth (9.1%), strong Greenbrook performance (+16.8%), margin expansion (to 51.1%), reduced OPEX (-12%), an improved net loss and a positive adjusted EBITDA, plus strengthened cash and an ATM raise. These positives were balanced against execution and timing risks centered on NeuroStar's transition (NeuroStar revenue down 2.7% and sessions down double digits due to inventory normalization and mix shifts), underused clinic capacity (~40%), potential short-term revenue choppiness as customers migrate to new purchase/lease models, and dependence on external regulatory timelines for psychedelics. On balance, the company demonstrated tangible progress toward profitability and cash generation while acknowledging near-term mix and execution challenges.View all STIM earnings summariesSTIM Stock 12 Month Forecast
Average Price Target
$5.00
▲(189.02% Upside)
Technical Analysis
Ownership Overview
28.52% Insiders
5.09% Mutual Funds
36.11% Other Institutional Investors
26.85% Public Companies and
Individual Investors